Document Detail

Onyx(®) in the management of cranial arteriovenous malformations.
MedLine Citation:
PMID:  23895072     Owner:  NLM     Status:  In-Data-Review    
The ethylene vinyl alcohol copolymer, Onyx(®) (ev3, Inc., MN, USA), is an embolic agent used in the management of arteriovenous malformations (AVMs) and was approved by the US FDA in 2005. Use of Onyx has resulted in higher curative rates compared with previous embolic agents such as N-butyl-2-cyanoacrylate. Onyx has several advantages over previous embolic agents. For instance, Onyx is a copolymer and does not adhere to catheters but solidifies slowly owing to the diffusion of its solvent dimethyl sulfoxide. This review focuses on different results obtained from the experience of different neurointerventionalists with an emphasis on the aim to cure. The studies presented are compared in terms of curative rates, morbidity and mortality. Ideas are presented for future treatment options for AVM rupture using nanotargeted therapy with the guide of specific markers highly expressed on the surface of cells or tissues of interest. Such nanotargeted therapy might transform AVM treatment with new embolic agents.
Jalal Jalaly; John Dalfino; Shaker A Mousa
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of medical devices     Volume:  10     ISSN:  1745-2422     ISO Abbreviation:  Expert Rev Med Devices     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-07-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230445     Medline TA:  Expert Rev Med Devices     Country:  England    
Other Details:
Languages:  eng     Pagination:  453-9     Citation Subset:  IM    
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  HeartWare miniaturized intrapericardial ventricular assist device: advantages and adverse events in ...
Next Document:  Current trends in aortic valve replacement: development of the rapid deployment EDWARDS INTUITY valv...